Answers are grounded in this paper and cite their sources.
Background/Objectives: Sepsis involves a heterogeneous and dynamic immune response, characterized by the coexistence of hyperinflammation and immunosuppression. This complexity limits the efficacy of immunomodulatory therapies in unselected populations and supports the development of biomarker-guided precision immunotherapy. Methods: A narrative review of publications indexed in PubMed between 2019 and 2026 was conducted. Clinical trials, systematic reviews, and meta-analyses investigating immunotherapeutic strategies in sepsis were prioritized. Additional relevant publications were identified through reference screening. Results: Current approaches target hyperinflammation, restore innate and adaptive immunity, or modulate humoral responses. Anakinra and biomarker-guided strategies have shown promising signals in selected subgroups, whereas studies of nangibotide, interferon-γ, interleukin-7, granulocyte-macrophage colony-stimulating factor, immune checkpoint inhibitors, thymosin α1, and immunoglobulins have yielded heterogeneous results. Despite improvements in immune parameters or organ function reported with some interventions, a consistent mortality benefit has not been established across the general sepsis population. Most available biomarkers provide prognostic or phenotypic information rather than validated predictions of treatment response. Conclusions: Precision immunotherapy represents a promising direction in sepsis management, but its clinical translation remains challenging. Distinguishing prognostic from predictive biomarkers and integrating clinical, cellular, molecular, and functional parameters may improve patient stratification. Dynamic immune monitoring and multimarker classification could support individualized treatment selection and timing. However, prospective validation of treatment–biomarker interactions, standardized assessment methods, and robust evidence of meaningful clinical benefit are essential before widespread implementation.
No takes yet. Share an insight, caveat, or question.
Piccioni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: